|
|
|
|
| LEADER |
03830nmm a2201009 u 4500 |
| 001 |
EB002165508 |
| 003 |
EBX01000000000000001303287 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230607 ||| eng |
| 020 |
|
|
|a 9780841214675
|
| 050 |
|
4 |
|a RS431.P75
|
| 100 |
1 |
|
|a Cleland, Jeffrey L.
|e [editor]
|
| 245 |
0 |
0 |
|a Formulation and delivery of proteins and peptides
|c Jeffrey L. Cleland, editor; Robert Langer, editor
|
| 260 |
|
|
|a Washington, DC
|b American Chemical Society
|c 1994, 1994
|
| 300 |
|
|
|a 380 pages
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references and index
|
| 653 |
|
|
|a Pharmaceutical preparations / analysis
|
| 653 |
|
|
|a MEDICAL / Pharmacology / bisacsh
|
| 653 |
|
|
|a Freeze-drying / Stability
|
| 653 |
|
|
|a Fish Proteins / chemistry
|
| 653 |
|
|
|a Nanoparticles / therapeutic use
|
| 653 |
|
|
|a Proteins / therapeutic use
|
| 653 |
|
|
|a Stabilizing agents
|
| 653 |
|
|
|a Deoxyribonucleases
|
| 653 |
|
|
|a Proteins / analysis
|
| 653 |
|
|
|a Peptides / analysis
|
| 653 |
|
|
|a DNA, Recombinant / therapeutic use
|
| 653 |
|
|
|a Cryopreservation
|
| 653 |
|
|
|a Freeze Drying
|
| 653 |
|
|
|a Freezing
|
| 653 |
|
|
|a Monoclonal antibodies
|
| 653 |
|
|
|a Dosage Forms
|
| 653 |
|
|
|a Chemicals / Stability
|
| 653 |
|
|
|a Parenteral therapy / Analysis
|
| 653 |
|
|
|a Models, Animal
|
| 653 |
|
|
|a Infrared spectroscopy / Analysis
|
| 653 |
|
|
|a Peptides / Stability
|
| 653 |
|
|
|a Peptide drugs / Design
|
| 653 |
|
|
|a Aerosols
|
| 653 |
|
|
|a Fibroblast growth factors / Research
|
| 653 |
|
|
|a Spectroscopy, Fourier Transform Infrared
|
| 653 |
|
|
|a Protein drugs / Dosage forms
|
| 653 |
|
|
|a Sucrose / Analysis / Research
|
| 653 |
|
|
|a Proteins / chemistry
|
| 653 |
|
|
|a Protein drugs / Design
|
| 653 |
|
|
|a Aspartic Acid Proteases / chemistry
|
| 653 |
|
|
|a Cryopreservation of organs, tissues, etc
|
| 653 |
|
|
|a Botulinum Toxins / chemistry
|
| 653 |
|
|
|a Trehalose / chemistry
|
| 653 |
|
|
|a Peptides / therapeutic use
|
| 653 |
|
|
|a Oligomerization
|
| 653 |
|
|
|a Solid state chemistry
|
| 653 |
|
|
|a Antigens / Research
|
| 653 |
|
|
|a Polyesters / therapeutic use
|
| 653 |
|
|
|a Peptide drugs / Development
|
| 653 |
|
|
|a Atomizers / Collection and preservation
|
| 653 |
|
|
|a Botulinum toxin
|
| 653 |
|
|
|a Recombinant DNA.
|
| 653 |
|
|
|a Lysozyme / Analysis
|
| 653 |
|
|
|a Peptide drugs / Dosage forms
|
| 653 |
|
|
|a Immunoglobulin G / analysis
|
| 653 |
|
|
|a Protein drugs / Oxidation
|
| 653 |
|
|
|a Fibroblast Growth Factor 2
|
| 653 |
|
|
|a Aerosols / therapeutic use
|
| 653 |
|
|
|a Deoxyribonucleases / therapeutic use
|
| 653 |
|
|
|a Trehalose / Stability / Analysis
|
| 653 |
|
|
|a Muramidase / analysis
|
| 653 |
|
|
|a Drug Delivery Systems
|
| 653 |
|
|
|a Disulfides / chemistry
|
| 653 |
|
|
|a Polyanhydrides / therapeutic use
|
| 653 |
|
|
|a Nanoparticles / Research
|
| 653 |
|
|
|a Polymers / therapeutic use
|
| 653 |
|
|
|a Spectrophotometry, Infrared
|
| 653 |
|
|
|a Protein drugs / Development
|
| 653 |
|
|
|a Antibodies, Monoclonal / analysis
|
| 653 |
|
|
|a Fourier transform infrared spectroscopy
|
| 653 |
|
|
|a Oligopeptides / chemistry
|
| 700 |
1 |
|
|a Langer, Robert S.
|e [editor]
|
| 710 |
2 |
|
|a American Chemical Society
|b Division of Biochemical Technology
|
| 710 |
2 |
|
|a American Chemical Society
|b Meeting ( 1993, Denver, Colorado)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b ACS
|a ACS Symposium Series
|
| 490 |
0 |
|
|a ACS symposium series
|
| 500 |
|
|
|a "Developed from a symposium sponsored by the Division of Biochemical Technology at the 205th National Meeting of the American Chemical Society, Denver, Colorado, March 28-April 2, 1993.". - Distributed in print by Oxford University Press
|
| 856 |
4 |
0 |
|u https://pubs.acs.org/doi/book/10.1021/bk-1994-0567
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615/.19
|